{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:09:26Z","timestamp":1793045366616,"version":"4.5.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In type 2 diabetes mellitus (T2DM), the antidiuretic system participates in the adaptation to osmotic diuresis further increasing urinary osmolality by reducing the electrolyte-free water clearance. Sodium glucose co-transporter type 2 inhibitors (SGLT2i) emphasize this mechanism, promoting persistent glycosuria and natriuresis, but also induce a greater reduction of interstitial fluids than traditional diuretics. The preservation of osmotic homeostasis is the main task of the antidiuretic system and, in turn, intracellular dehydration the main drive to vasopressin (AVP) secretion. Copeptin is a stable fragment of the AVP precursor co-secreted with AVP in an equimolar amount.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the copeptin adaptive response to SGLT2i, as well as the induced changes in body fluid distribution in T2DM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The GliRACo study was a prospective, multicenter, observational research. Twenty-six consecutive adult patients with T2DM were recruited and randomly assigned to empagliflozin or dapagliflozin treatment. Copeptin, plasma renin activity, aldosterone and natriuretic peptides were evaluated at baseline (T0) and then 30 (T30) and 90 days (T90) after SGLT2i starting. Bioelectrical impedance vector analysis (BIVA) and ambulatory blood pressure monitoring were performed at T0 and T90.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among endocrine biomarkers, only copeptin increased at T30, showing subsequent stability (7.5 pmol\/L at T0, 9.8 pmol\/L at T30, 9.5 pmol\/L at T90; <jats:italic>p<\/jats:italic> = 0.001). BIVA recorded an overall tendency to dehydration at T90 with a stable proportion between extra- and intracellular fluid volumes. Twelve patients (46.1%) had a BIVA overhydration pattern at baseline and 7 of them (58.3%) resolved this condition at T90. Total body water content, extra and intracellular fluid changes were significantly affected by the underlying overhydration condition (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), while copeptin did not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with T2DM, SGLT2i promote the release of AVP, thus compensating for persistent osmotic diuresis. This mainly occurs because of a proportional dehydration process between intra and extracellular fluid (i.e., intracellular dehydration rather than extracellular dehydration). The extent of fluid reduction, but not the copeptin response, is affected by the patient\u2019s baseline volume conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>, identifier NCT03917758.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2023.1098404","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:39:50Z","timestamp":1679287190000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandro Maria","family":"Berton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Parasiliti-Caprino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bioletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rumbolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ponzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Settanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Mengozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Maccario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Silvio","family":"Benso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1053\/meta.2002.34052","article-title":"Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas.","volume":"51","author":"Abu-Basha","year":"2002","journal-title":"Metabolism"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005686","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: A systematic review and meta-analysis.","volume":"6","author":"Baker","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1210\/jc.2010-2499","article-title":"Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States.","volume":"96","author":"Balanescu","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000045879","article-title":"Vasopressin and diabetes mellitus.","volume":"87","author":"Bankir","year":"2001","journal-title":"Nephron"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-023-00430-0","article-title":"Long-term efficacy of empagliflozin as an add-on treatment for chronic SIAD: A case report and literature review.","author":"Bioletto","year":"2023","journal-title":"Hormones (Athens)"},{"key":"B6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cphy.c130017","article-title":"Dehydration: Physiology, assessment, and performance effects.","volume":"4","author":"Cheuvront","year":"2014","journal-title":"Compr. Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11154-019-09509-9","article-title":"Vasopressin and copeptin in health and disease.","volume":"20","author":"Christ-Crain","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors.","volume":"8","author":"Heerspink","year":"2019","journal-title":"J. Clin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jcjd.2018.03.006","article-title":"Copeptin and estimated insulin sensitivity in adults with and without type 1 diabetes: The CACTI study.","volume":"43","author":"Jensen","year":"2019","journal-title":"Can. J. Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11255-021-02943-2","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: A systematic review and meta-analysis.","volume":"54","author":"Kanbay","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0304-4165(79)90371-4","article-title":"The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis.","volume":"588","author":"Keppens","year":"1979","journal-title":"Biochim. Biophys. Acta."},{"key":"B13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/nu11040809","article-title":"Classification of hydration in clinical conditions: Indirect and direct approaches using bioimpedance.","volume":"11","author":"Lukaski","year":"2019","journal-title":"Nutrients"},{"key":"B15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diabet.2019.11.006","article-title":"SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.","volume":"46","author":"Lytvyn","year":"2020","journal-title":"Diabetes Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.1993.265.3.F361","article-title":"Insulin stimulates Na+, Cl-, Ca2+, and Mg2+ transports in TAL of mouse nephron: cross-potentiation with AVP.","author":"Mandon","year":"1993","journal-title":"Am. J. Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes.","volume":"51","author":"Marathias","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 inhibitors: Role of metabolic energy and water conservation.","volume":"17","author":"Marton","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium\u2013glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"F1031","DOI":"10.1152\/ajprenal.00128.2005","article-title":"Stimulation of Na+ transport by AVP is independent of PKA phosphorylation of the Na-K-ATPase in collecting duct principal cells.","volume":"289","author":"Mordasini","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1161\/hy1001.092641","article-title":"Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung.","volume":"38","author":"Nicco","year":"2001","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/HJH.0000000000002441","article-title":"Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension.","volume":"38","author":"Parasiliti-Caprino","year":"2020","journal-title":"J. Hypertens."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s40618-020-01465-5","article-title":"Neuroendocrine predictors of vasoplegia after cardiopulmonary bypass.","volume":"44","author":"Pasero","year":"2020","journal-title":"J. Endocrinol. Invest."},{"key":"B25","author":"Piccoli","year":"2002","journal-title":"BIVA software [Internet]."},{"key":"B26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ajcn\/61.2.269","article-title":"Bivariate normal values of the bioelectrical impedance vector in adult and elderly populations.","volume":"61","author":"Piccoli","year":"1995","journal-title":"Am. J. Clin. Nutr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis.","volume":"31","author":"Refardt","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MNH.0000000000000335","article-title":"Vasopressin and diabetic nephropathy.","volume":"26","author":"Roussel","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.","volume":"71","author":"Sano","year":"2018","journal-title":"J. Cardiol. Jpn. Coll. Cardiol. (Nippon Sinzobyo Gakkai)"},{"key":"B31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/dmrr.1239","article-title":"Cardiovascular autonomic neuropathy in diabetes: Clinical impact, assessment, diagnosis, and management.","volume":"27","author":"Spallone","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0823-9","article-title":"Dysregulation of the renin-angiotensin system and the vasopressinergic system interactions in cardiovascular disorders.","volume":"20","author":"Szczepanska-Sadowska","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.2337\/dc13-0683","article-title":"Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.","volume":"36","author":"Velho","year":"2013","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S1521-690X(03)00049-6","article-title":"Disorders of body water homeostasis.","volume":"17","author":"Verbalis","year":"2003","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1042\/bj1760893","article-title":"Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions.","volume":"176","author":"Whitton","year":"1978","journal-title":"Biochem. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1097\/HJH.0000000000001961","article-title":"2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension ESC\/ESH task force for the management of arterial hypertension.","volume":"36","author":"Williams","year":"2018","journal-title":"J. Hypertens."},{"key":"B38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1098404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T04:39:54Z","timestamp":1679287194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1098404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":39,"alternative-id":["10.3389\/fnins.2023.1098404"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1098404","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"article-number":"1098404"}}